Cargando…

Is It Worth Continuing Sexual Rehabilitation after Radical Prostatectomy with Intracavernous Injection of Alprostadil for More than 1 Year?

INTRODUCTION: Intracavernous alprostadil injection (IAI) is a widely used treatment for sexual rehabilitation (SR) after radical prostatectomy (RP). It is unknown whether the continuation of IAI beyond 1 year continues to improve erectile function. AIMS: To assess evolution of sexual function in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yiou, René, Bütow, Zentia, Parisot, Juliette, Binhas, Michele, Lingombet, Odile, Augustin, Deborah, de la Taille, Alexandre, Audureau, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380913/
https://www.ncbi.nlm.nih.gov/pubmed/25844174
http://dx.doi.org/10.1002/sm2.51
_version_ 1782364364723978240
author Yiou, René
Bütow, Zentia
Parisot, Juliette
Binhas, Michele
Lingombet, Odile
Augustin, Deborah
de la Taille, Alexandre
Audureau, Etienne
author_facet Yiou, René
Bütow, Zentia
Parisot, Juliette
Binhas, Michele
Lingombet, Odile
Augustin, Deborah
de la Taille, Alexandre
Audureau, Etienne
author_sort Yiou, René
collection PubMed
description INTRODUCTION: Intracavernous alprostadil injection (IAI) is a widely used treatment for sexual rehabilitation (SR) after radical prostatectomy (RP). It is unknown whether the continuation of IAI beyond 1 year continues to improve erectile function. AIMS: To assess evolution of sexual function in patients using IAI who are nonresponsive to phosphodiesterase type 5 inhibitors (PDE5i) between 12 (M12) and 24 (M24) months after RP. METHODS: We retrospectively studied 75 men with a nerve-sparing laparoscopic RP, who had normal preoperative erectile function, and who regularly used IAI for SR for at least 24 months. At M12, no patients had responded to PDE5i. MAIN OUTCOME MEASURES: At 12 and 24 months, sexual function was assessed with the UCLA Prostate Cancer Index (UCLA-PCI), International Index of Erectile Function (IIEF)-15, and erection hardness score (EHS) with and without IAI. We also assessed the satisfaction rate with IAI, injection-related penile pain, and satisfaction of treatment. Statistical analysis was performed by using t-tests for paired data and Spearman's rho correlation coefficients to assess the relationships between scores at M12 and M24. RESULTS: Improvement of nocturnal erection was noted (UCLA-PCI, question 25); however, no significant difference was found for IIEF-erectile function with (19.60 ± 9.80 vs. 18.07 ± 10.44) and without IAI (4.63 ± 2.93 vs. 4.92 ± 4.15), UCLA-PCI-sexual bother (37.14 ± 21.45 vs. 37.54 ± 19.67), nor the EHS score with (2.97 ± 1.30 vs. 2.57 ± 1.30) and without IAI (0.67 ± 1.11 vs. 0.76 ± 0.10). The rate of satisfaction with treatment decreased over time (66.6% vs. 46.7%, P = 0.013). Improved response to IAI at M12 was not correlated to improvement in spontaneous erections at M24. CONCLUSION: The response to IAI remained stable after 2 years of treatment, and no significant improvement of spontaneous erections during intercourse attempts was found between M12 and M24. Patients should be informed of the limited effect of IAI on natural erections after 1 year. Yiou R, Bütow Z, Parisot J, Binhas M, Lingombet O, Augustin D, de la Taille A, and Audureau E. Is it worth continuing sexual rehabilitation after radical prostatectomy with intracavernous injection of alprostadil for more than 1 year? Sex Med 2015;3:42–48.
format Online
Article
Text
id pubmed-4380913
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-43809132015-04-03 Is It Worth Continuing Sexual Rehabilitation after Radical Prostatectomy with Intracavernous Injection of Alprostadil for More than 1 Year? Yiou, René Bütow, Zentia Parisot, Juliette Binhas, Michele Lingombet, Odile Augustin, Deborah de la Taille, Alexandre Audureau, Etienne Sex Med Original Research—Erectile Dysfunction INTRODUCTION: Intracavernous alprostadil injection (IAI) is a widely used treatment for sexual rehabilitation (SR) after radical prostatectomy (RP). It is unknown whether the continuation of IAI beyond 1 year continues to improve erectile function. AIMS: To assess evolution of sexual function in patients using IAI who are nonresponsive to phosphodiesterase type 5 inhibitors (PDE5i) between 12 (M12) and 24 (M24) months after RP. METHODS: We retrospectively studied 75 men with a nerve-sparing laparoscopic RP, who had normal preoperative erectile function, and who regularly used IAI for SR for at least 24 months. At M12, no patients had responded to PDE5i. MAIN OUTCOME MEASURES: At 12 and 24 months, sexual function was assessed with the UCLA Prostate Cancer Index (UCLA-PCI), International Index of Erectile Function (IIEF)-15, and erection hardness score (EHS) with and without IAI. We also assessed the satisfaction rate with IAI, injection-related penile pain, and satisfaction of treatment. Statistical analysis was performed by using t-tests for paired data and Spearman's rho correlation coefficients to assess the relationships between scores at M12 and M24. RESULTS: Improvement of nocturnal erection was noted (UCLA-PCI, question 25); however, no significant difference was found for IIEF-erectile function with (19.60 ± 9.80 vs. 18.07 ± 10.44) and without IAI (4.63 ± 2.93 vs. 4.92 ± 4.15), UCLA-PCI-sexual bother (37.14 ± 21.45 vs. 37.54 ± 19.67), nor the EHS score with (2.97 ± 1.30 vs. 2.57 ± 1.30) and without IAI (0.67 ± 1.11 vs. 0.76 ± 0.10). The rate of satisfaction with treatment decreased over time (66.6% vs. 46.7%, P = 0.013). Improved response to IAI at M12 was not correlated to improvement in spontaneous erections at M24. CONCLUSION: The response to IAI remained stable after 2 years of treatment, and no significant improvement of spontaneous erections during intercourse attempts was found between M12 and M24. Patients should be informed of the limited effect of IAI on natural erections after 1 year. Yiou R, Bütow Z, Parisot J, Binhas M, Lingombet O, Augustin D, de la Taille A, and Audureau E. Is it worth continuing sexual rehabilitation after radical prostatectomy with intracavernous injection of alprostadil for more than 1 year? Sex Med 2015;3:42–48. BlackWell Publishing Ltd 2015-03 2014-12-02 /pmc/articles/PMC4380913/ /pubmed/25844174 http://dx.doi.org/10.1002/sm2.51 Text en © 2014 The Authors. Sexual Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Sexual Medicine. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research—Erectile Dysfunction
Yiou, René
Bütow, Zentia
Parisot, Juliette
Binhas, Michele
Lingombet, Odile
Augustin, Deborah
de la Taille, Alexandre
Audureau, Etienne
Is It Worth Continuing Sexual Rehabilitation after Radical Prostatectomy with Intracavernous Injection of Alprostadil for More than 1 Year?
title Is It Worth Continuing Sexual Rehabilitation after Radical Prostatectomy with Intracavernous Injection of Alprostadil for More than 1 Year?
title_full Is It Worth Continuing Sexual Rehabilitation after Radical Prostatectomy with Intracavernous Injection of Alprostadil for More than 1 Year?
title_fullStr Is It Worth Continuing Sexual Rehabilitation after Radical Prostatectomy with Intracavernous Injection of Alprostadil for More than 1 Year?
title_full_unstemmed Is It Worth Continuing Sexual Rehabilitation after Radical Prostatectomy with Intracavernous Injection of Alprostadil for More than 1 Year?
title_short Is It Worth Continuing Sexual Rehabilitation after Radical Prostatectomy with Intracavernous Injection of Alprostadil for More than 1 Year?
title_sort is it worth continuing sexual rehabilitation after radical prostatectomy with intracavernous injection of alprostadil for more than 1 year?
topic Original Research—Erectile Dysfunction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380913/
https://www.ncbi.nlm.nih.gov/pubmed/25844174
http://dx.doi.org/10.1002/sm2.51
work_keys_str_mv AT yiourene isitworthcontinuingsexualrehabilitationafterradicalprostatectomywithintracavernousinjectionofalprostadilformorethan1year
AT butowzentia isitworthcontinuingsexualrehabilitationafterradicalprostatectomywithintracavernousinjectionofalprostadilformorethan1year
AT parisotjuliette isitworthcontinuingsexualrehabilitationafterradicalprostatectomywithintracavernousinjectionofalprostadilformorethan1year
AT binhasmichele isitworthcontinuingsexualrehabilitationafterradicalprostatectomywithintracavernousinjectionofalprostadilformorethan1year
AT lingombetodile isitworthcontinuingsexualrehabilitationafterradicalprostatectomywithintracavernousinjectionofalprostadilformorethan1year
AT augustindeborah isitworthcontinuingsexualrehabilitationafterradicalprostatectomywithintracavernousinjectionofalprostadilformorethan1year
AT delataillealexandre isitworthcontinuingsexualrehabilitationafterradicalprostatectomywithintracavernousinjectionofalprostadilformorethan1year
AT audureauetienne isitworthcontinuingsexualrehabilitationafterradicalprostatectomywithintracavernousinjectionofalprostadilformorethan1year